Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19)

Background. Given the rapidly evolving pandemic of COVID-19 in 2020, authorities focused on the repurposing of available drugs to develop timely and cost-effective therapeutic strategies. Evidence suggested the potential utility of remdesivir in the framework of an early access program. REMDECO-19 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zerbit, Jeremie, Detroit, Marion, Chevret, Sylvie, Pene, Frederic, Luyt, Charles-Edouard, Ghosn, Jade, Eyvrard, Frederic, Martin-Blondel, Guillaume, Sarton, Benjamine, Clere-Jehl, Raphael, Moine, Pierre, Cransac, Amelie, Andreu, Pascal, Labruyère, Marie, Albertini, Laetitia, Huon, Jean-François, Roge, Pauline, Bernard, Lise, Farines-Raffoul, Magali, Villiet, Maxime, Venet, Arnaud, Dumont, Louis Marie, Kaiser, Jean-Daniel, Chapuis, Claire, Goehringer, François, Barbier, François, Desjardins, Stephane, Benzidi, Younes, Abbas, Nora, Guerin, Corinne, Batista, Rui, Llitjos, Jean-François, Kroemer, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654065/
https://www.ncbi.nlm.nih.gov/pubmed/36362773
http://dx.doi.org/10.3390/jcm11216545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654065/
https://www.ncbi.nlm.nih.gov/pubmed/36362773
http://dx.doi.org/10.3390/jcm11216545

Ejemplares similares